MENU
HELX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Jul 06, 2026

HELX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for HELX moved above the 200-day moving average on June 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 223 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

HELX broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NYSE:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Guardant Health (NASDAQ:GH), Exact Sciences Corp (NASDAQ:EXAS), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 42.25B. The market cap for tickers in the group ranges from 218.73M to 1.07T. LLY holds the highest valuation in this group at 1.07T. The lowest valued company is VYGR at 218.73M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 3%. For the same ETF, the average monthly price growth was 15%, and the average quarterly price growth was 8%. RCKT experienced the highest price growth at 14%, while VCYT experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -6%. For the same stocks of the ETF, the average monthly volume growth was -28% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 64
Price Growth Rating: 40
SMR Rating: 78
Profit Risk Rating: 76
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com
HELX sees its 50-day moving average cross bullishly above its 200-day moving average